苦参素联合胸腺肽α1治疗失代偿期肝硬化的抗病毒效果观察

摘要

Objective To explore the application of oxymatrine and thymosin α1 in treatment of decompensated cirrhosis. Methods 52 cases of patients with decompensative hepatic cirrhosis C. Patients receive the protecting liver, debasing enzyme and albumin basic treatment at the same time in two group. Observation group increased kurarinone, thymosinα1 therapy, comparative effcacy of two groups. Results After treatment, the patient's symptom improvement, Child-Pugh score, serum HCV-RNA and hepatic function improvement in observation group better than the control group, P<0.05. Conclusion Applications oxymatrine and thymosinα1, can effectively inhibit the expression of virus, protect liver cells and reduce liver damage, the clinical effcacy is safe and effective.%目的：研究苦参素与胸腺肽α1治疗失代偿期丙型肝炎肝硬化过程中的应用价值。方法选择52例丙型肝炎肝硬化失代偿期患者进行分组，同时接受保肝降酶与白蛋白基础治疗，观察组增加苦参素、胸腺肽α1治疗，观察对比两组治疗效果。结果治疗后，观察组患者症状改善情况、Child-Pugh评分以及血清HCV-RNA、肝功能改善程度优于对照组，P＜0.05。结论应用苦参素与胸腺肽α1进行治疗，可有效抑制病毒的表达，保护肝细胞，减轻肝损伤，疗效安全可靠。